Sera Prognostics, Inc. (NASDAQ:SERA) Director Joshua Phillips Sells 12,163 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) Director Joshua Phillips sold 12,163 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $6.39, for a total transaction of $77,721.57. Following the completion of the transaction, the director now owns 2 shares in the company, valued at $12.78. This trade represents a 99.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Sera Prognostics Price Performance

Sera Prognostics stock traded up $0.04 during midday trading on Tuesday, hitting $6.37. The company’s stock had a trading volume of 134,610 shares, compared to its average volume of 143,614. The company has a 50-day moving average price of $7.44 and a two-hundred day moving average price of $7.31. Sera Prognostics, Inc. has a 1-year low of $4.98 and a 1-year high of $12.35. The company has a market cap of $215.13 million, a price-to-earnings ratio of -6.43 and a beta of 0.86.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.09 million. During the same period in the prior year, the business posted ($0.23) EPS. Sell-side analysts forecast that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Institutional Trading of Sera Prognostics

Institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its holdings in shares of Sera Prognostics by 7,357.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company’s stock valued at $6,902,000 after purchasing an additional 873,002 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Sera Prognostics by 100.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock worth $892,000 after buying an additional 75,441 shares during the last quarter. Geode Capital Management LLC boosted its stake in Sera Prognostics by 8.9% in the third quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock valued at $4,578,000 after buying an additional 47,969 shares in the last quarter. State Street Corp grew its position in Sera Prognostics by 8.8% in the third quarter. State Street Corp now owns 425,093 shares of the company’s stock valued at $3,316,000 after acquiring an additional 34,479 shares during the last quarter. Finally, Rhumbline Advisers acquired a new position in Sera Prognostics during the second quarter worth about $190,000. 54.64% of the stock is currently owned by institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.